Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjusted hypervolemic hemodilution in acute ischemic stroke.

M Koller1, P Haenny, K Hess

  • 1Medical Clinic, University Hospital, Zurich, Switzerland.

Stroke
|October 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cephalopod-inspired jetting devices for gastrointestinal drug delivery.

Nature·2024
Same author

Canadian Surgery Forum 2018: St. John's, NL Sept. 13-15, 2018.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

The vulnerable blood.

Hamostaseologie·2018
Same author

First description of a local <i>Coprinopsis cinerea</i> skin and soft tissue infection.

New microbes and new infections·2018
Same author

Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors.

Archives of dermatological research·2016

Hypervolemic hemodilution therapy improved neurological function and reduced disability in acute ischemic stroke patients. This treatment was well-tolerated and showed lasting benefits for stroke recovery.

Area of Science:

  • Neurology
  • Cardiovascular Medicine

Background:

  • Acute ischemic stroke, particularly involving the middle cerebral artery, presents a significant clinical challenge.
  • Early intervention is crucial for mitigating neuronal damage and improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of adjusted hypervolemic hemodilution in patients with acute ischemic stroke.
  • To assess the impact of this intervention on neurological function, disability, and mortality over a 90-day period.

Main Methods:

  • Prospective randomized trial involving 47 patients with acute ischemic stroke (middle cerebral artery, <24 hours).
  • Intervention group received adjusted hypervolemic hemodilution targeting a hematocrit of 30-35% using dextran 40, venesections, and crystalloid infusions.
  • Control group received standard care. Follow-up at 90 days.

Related Experiment Videos

Main Results:

  • No significant difference in mortality rates between the hemodilution and control groups.
  • Significant improvements in relative neurologic function were observed in the hemodilution group at days 8, 21, and 90.
  • Enhanced fine motor control and reduced severe disability frequency in the hemodilution group on days 8 and 21.
  • Plasma viscosity was unaffected by dextran 40 infusions.

Conclusions:

  • Vigorous hypervolemic hemodilution is well-tolerated in acute ischemic stroke patients.
  • This therapeutic approach significantly improves early neurologic outcomes, with benefits persisting for at least 3 months.
  • Hypervolemic hemodilution represents a promising strategy for managing acute ischemic stroke.